Multivariable analyses of relapse, death in complete remission, and overall survival
| . | Relapse . | Death in CR . | OS . | |||
|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | |
| t-AML | ||||||
| intensively treated (age 16-60 y) | 1.16 | .39 | 2.74 | < .0001 | 1.35 | .01 |
| less intensively treated (age > 60 y) | 2.13 | .02 | 1.23 | .22 | 1.14 | .34 |
| Age (difference of 10 y) | 1.11 | .003 | 1.34 | .0001 | 1.34 | < .0001 |
| Male sex | 1.03 | .62 | 1.23 | .18 | 1.10 | .06 |
| Cytogenetic favorable-risk* | 0.59 | < .0001 | 0.38 | < .0001 | 0.50 | < .0001 |
| Cytogenetic adverse-risk* | 1.55 | < .0001 | 1.49 | .07 | 2.07 | < .0001 |
| NPM1 mutation | 0.69 | < .0001 | 0.67 | .04 | 0.78 | < .0001 |
| FLT3-ITD | 1.42 | < .0001 | 1.61 | .01 | 1.51 | < .0001 |
| Logarithm of WBC | 1.14 | < .0001 | 1.01 | .82 | 1.09 | < .0001 |
| Logarithm of platelets | 0.99 | .80 | 0.93 | .37 | 0.94 | .02 |
| BM blasts (difference of 10%) | 1.00 | .11 | 1.00 | .78 | 1.00 | .51 |
| PB blasts (difference of 10%) | 1.00 | .17 | 1.01 | .54 | 1.02 | .04 |
| . | Relapse . | Death in CR . | OS . | |||
|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | |
| t-AML | ||||||
| intensively treated (age 16-60 y) | 1.16 | .39 | 2.74 | < .0001 | 1.35 | .01 |
| less intensively treated (age > 60 y) | 2.13 | .02 | 1.23 | .22 | 1.14 | .34 |
| Age (difference of 10 y) | 1.11 | .003 | 1.34 | .0001 | 1.34 | < .0001 |
| Male sex | 1.03 | .62 | 1.23 | .18 | 1.10 | .06 |
| Cytogenetic favorable-risk* | 0.59 | < .0001 | 0.38 | < .0001 | 0.50 | < .0001 |
| Cytogenetic adverse-risk* | 1.55 | < .0001 | 1.49 | .07 | 2.07 | < .0001 |
| NPM1 mutation | 0.69 | < .0001 | 0.67 | .04 | 0.78 | < .0001 |
| FLT3-ITD | 1.42 | < .0001 | 1.61 | .01 | 1.51 | < .0001 |
| Logarithm of WBC | 1.14 | < .0001 | 1.01 | .82 | 1.09 | < .0001 |
| Logarithm of platelets | 0.99 | .80 | 0.93 | .37 | 0.94 | .02 |
| BM blasts (difference of 10%) | 1.00 | .11 | 1.00 | .78 | 1.00 | .51 |
| PB blasts (difference of 10%) | 1.00 | .17 | 1.01 | .54 | 1.02 | .04 |
BM indicates bone marrow; CR, complete remission; HR, hazard ratio; ITD, internal tandem duplication; OS, overall survival; PB, peripheral blood; and WBC, white blood count.
According to Döhner et al28 ; models were stratified for the 6 different treatment trials.